# IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

> **NCT05359445** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Immatics Biotechnologies GmbH** · enrollment: 95 (estimated)

## Conditions studied

- Refractory Cancer
- Recurrent Cancer
- Solid Tumor, Adult
- Cancer

## Interventions

- **BIOLOGICAL:** IMA401 (Phase Ia)
- **BIOLOGICAL:** Pembrolizumab (Phase Ia)
- **BIOLOGICAL:** IMA 401 (Phase Ib)

## Key facts

- **NCT ID:** NCT05359445
- **Lead sponsor:** Immatics Biotechnologies GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-19
- **Primary completion:** 2026-03-18
- **Final completion:** 2029-12
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359445, "IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT05359445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*